Bjorkman, Pamela J.

Klein, Joshua S.

PLoS Pathogens

English

PubMed

Caltech Authors - Main

Few and Far Between: How HIV May Be Evading Antibody Avidity

Joshua S Klein

Pamela J Bjorkman

Directory of Open Access Journals

Few and far between: how HIV may be evading antibody avidity.

A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody.

A dynamical study of antibody-antigen encounter reactions.

A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type

Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein.

Antibody crosscompetition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Antibody neutralization and escape by HIV-1.

Antibody vs. HIV in a clash of evolutionary titans.

Binding parameters of antibodies: pseudo-affinity and other misconceptions.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:

Cellular immune responses to HIV.

Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.

Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know.

Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ.

Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with n a t i v ev i r a lg p

Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120.

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155–1159. 7 0 .C r o o k sE T ,J i a n gP ,F r a n t iM ,W o n gS

Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency.

Distribution and three-dimensional structure of AIDS virus envelope spikes.

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 3:

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary deterPLoS Pathogens |

Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

GP120: target for neutralizing HIV-1 antibodies.

Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

HIV vaccine trial results–an opening for further research.

HIV-1 and influenza antibodies: seeing antigens in new ways.

HIV-1 evades antibodymediated neutralization through conformational masking of receptor-binding sites.

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Immunobiology.

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng Des Sel

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Investigations in the design and characterization of HIV-1 neutralizing molecules. Pasadena: California Institute of Technology.

Molecular architecture of native HIV-1 gp120 trimers.

Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail.

Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry.

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Regoes RR

Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.

Structural basis for HIV-1 neutralization by a gp41 fusion intermediatedirected antibody.

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals antiCD4 polyreactivity. Nat Struct Mol Biol.

Structure of a human rhinovirusbivalently bound antibody complex: implications for viral neutralization and antibody flexibility.

Structure of a V3-containing HIV-1 gp120 core.

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Structure of an unliganded simian immunodeficiency virus gp120 core.

Structures of HIV-1 gp120 envelope glycoproteins from laboratoryadapted and primary isolates.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–.2 mannose residues on the outer face of gp120.

The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance.

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

The influence of virus structure on antibody responses and virus serotype formation.

The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity.

Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells.

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 i n f e c t i o ni nT h a i l a n d .NE n g lJM e

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Vaccines: correlates of vaccineinduced immunity.

Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments.

Zernike phase contrast electron microscopy of ice-embedded influenza A virus.

https://authors.library.caltech.edu/18991/1/Klein2010p10565Plos_Pathog.pdf

Few and Far Between: How HIV May Be Evading Antibody Avidity

Abstract

Similar works

Full text

Available Versions

Caltech Authors - Main

Directory of Open Access Journals